A new Lancet Commission, published this week, draws attention to the importance of awareness and knowledge among the general public, health workers and policymakers. At least 60% of cases are preventable.
Read in full: https://www.thelancet.com/commissions-do/hepatocellular-carcinoma
EXECUTIVE SUMMARY
Liver cancer is the sixth most common cancer and the third leading cause of cancer-related mortality globally. The number of new liver cancers will nearly double, from 0·87 million in 2022 to 1·52 million in 2050, if there is no change in the current trend. The Lancet Commission on hepatocellular carcinoma addresses the severity of hepatocellular carcinoma over the next 25 years. The Commission aims to define a goal for reducing the global hepatocellular carcinoma burden and outline ten evidence-based recommendation for actions. These recommendations cover various areas, including awareness campaigns, improvements in health-care delivery, and access to treatment, as well as policy and legislative changes.
A linked editorial notes: 'Awareness of the emerging importance of MASLD and MASH remains low among health-care providers and policy makers, impeding timely diagnosis and intervention.'
Reversing the rise of liver cancer
The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01530-2/fulltext
Best wishes, Neil
HIFA profile: Neil Pakenham-Walsh is coordinator of HIFA (Healthcare Information For All), a global health community that brings all stakeholders together around the shared goal of universal access to reliable healthcare information. HIFA has 20,000 members in 180 countries, interacting in four languages and representing all parts of the global evidence ecosystem. HIFA is administered by Global Healthcare Information Network, a UK-based nonprofit in official relations with the World Health Organization. Email: neil@hifa.org